54
Participants
Start Date
June 28, 2021
Primary Completion Date
March 4, 2024
Study Completion Date
March 4, 2024
Magrolimab
Administered intravenously
Azacitidine
Administered either subcutaneously or IV, 75 mg/milligram per square (m\^2) on Days 1 to 7 or Days 1 to 5, 8 and 9 during every cycle
Venetoclax
Administered orally at a dose of 100 mg on Day 1, 200 mg on Day 2, 400 mg on Days 3-28 during Cycle 1, followed by 400 mg on Days 1-28 during every cycle
Mitoxantrone
Administered intravenously, 8 mg/m\^2 on Days 1-5 during Cycle 1 to Cycle 3
Etoposide
Administered intravenously, 100 mg/m\^2 on Days 1-5 during Cycle 1 to Cycle 3
Cytarabine
Administered intravenously, 1000 mg/m\^2 on Days 1-5 during Cycle 1 to Cycle 3
CC-486
Administered orally, 300 mg on Days 1-14 during each cycle
The Alfred Hospital, Melbourne
Austin Health, Heidelberg
Royal Perth Hospital, Perth
Roswell Park Cancer Institute, Buffalo
Levine Cancer Institute, Charlotte
Sylvester Comprehensive Cancer Center, Miami
University of Alabama at Birmingham, Birmingham
Cleveland Clinic Foundation, Cleveland
Karmanos Cancer Institute, Detroit
Froedtert Hospital & the Medical College of Wisconsin, Milwaukee
The University of Chicago Medical Center, Chicago
Washington University School of Medicine, St Louis
OU Health, Stephenson Cancer Center, Oklahoma City
Baylor University Medical Center, Dallas
MD Anderson Cancer Center, Houston
USC/Norris Comprehensive Cancer Center, Los Angeles
Cedars-Sinai Medical Center, Samuel Oschin Comprehensive Cancer Institute, Los Angeles
City of Hope (City of Hope National Medical Center, City of Hope Medical Center), Duarte
Stanford Cancer Center, Palo Alto
Swedish Cancer Institute, Seattle
Oxford University Hospitals NHS Foundation Trust, Churchill Hospital, Oxford
Lead Sponsor
Gilead Sciences
INDUSTRY